Healthcare Industry News: HSMN NewsFeed
News Release - October 6, 2010
LDR Builds on Success of VerteBRIDGE(TM) with Launch of Two New Lateral Applications**LDR Completes Initial European Implantations of Its New VerteBRIDGE Lumbar Cages – the Only Avenue to Creating a Minimally Invasive Stand-Alone Construct from a Direct Lateral Approach
AUSTIN, Texas--(Healthcare Sales & Marketing Network)-- LDR, a total spine solution company, announced today the expansion of its lumbar VerteBRIDGE product offering following 2 years of successful clinical use of the ROI-A® ALIF Cage. The new applications offer a complete range of alternatives to currently adopted lateral approaches. The new direct lateral and oblique lumbar systems have been used successfully in Europe in more than 100 cases. Both implant systems incorporate the advantages of LDR’s stand-alone VerteBRIDGE Plating Technology and provide surgeons with new options for surgical approach to the lumbar spine.
Christophe Lavigne, CEO, elaborates, “We remain dedicated to bringing new and innovative solutions to the market that we believe offer distinct benefits to the patient and the surgeon. These new systems provide the first minimally invasive, zero-profile stand-alone solutions for lateral lumbar interbody fusion.”
Professor Jerome Allain, of the Henri Mondor Hospital in Paris, France, who has implanted more than 30 of these devices, comments, “I especially appreciate the addition of the specialized oblique ALIF implant for treating patients whose anatomy will not facilitate a direct anterior approach and for revision of a previous anterior surgery.”
LDR’s current VerteBRIDGE offerings, the ROI-A lumbar and ROI-C® cervical stand-alone cages, have enjoyed strong clinical success with more than 6,000 implantations since their launch in the US. Unlike other stand-alone systems that must be secured with screws inserted at oblique angles, the minimally invasive, zero-profile, stand-alone VerteBRIDGE Plating Technology utilizes a self-guided plating system that requires less exposure. The internal plating philosophy of the VerteBRIDGE system represents the only avenue to creating a minimally invasive stand-alone construct from a direct lateral approach.
Dr. Faissal Zahrawi, F.A.C.S., Director of the Spine Center of Celebration Health, Celebration, Florida, adds, “The VerteBRIDGE plating technology, which has been proven in the direct anterior applications of the ROI-A and ROI-C cages, is especially suited for stand-alone constructs implanted through an oblique or lateral approach to the lumbar spine.”
Dr. Pablo M. Lawner, of Sherman Oaks, California, notes, “The zero-profile VerteBRIDGE platform will soon offer a full range of minimally invasive surgical approach options to the lumbar spine, from straight anterior to direct lateral, accompanied by easy to use surgical instrumentation. It is exciting to offer these new treatment options to my patients.”
LDR has major offices in Europe, North America, South America, and Asia and has completed over 70,000 surgeries with its products worldwide. LDR works closely with surgeons to develop innovative spine products to help restore optimum stability and mobility to their patients, while making spine surgery more reproducible and easier to perform. More information is located at www.ldrholding.com.
For More Information:
©2010 LDR Holding Corporation, All Rights Reserved
** Lateral implants launched for commercial use outside of the USA. These implants are not yet available for use in the United States.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsShire Announces FDA Approval of Adynovate(R) for use in Children and Surgical Settings
Lancet Infectious Diseases Publishes Independent Double-Blind Study Validating MeMed's Immunoxpert(TM) Blood Test's Ability to Accurately Distinguish Between Bacterial and Viral Infections in Children
Neurim Pharmaceuticals Announces Positive Top-Line Results from Pivotal Phase III Trial of Paediatric Prolonged-Release Melatonin (PedPRM) for Sleep Disturbances in Children with Autism Spectrum Disorders (ASD)